课题基金 / 基金详情

A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICACY OF

A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICACY OF
IV 期、前瞻性、随机、开放标签的疗效评估
批准号：
8167080
负责人：
Judith S. Currier
金额：
$1.35万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
项目状态：
已结题
起止时间：
2009-12-01 至 2010-11-30
来源：
https://reporter.nih.gov/project-details/8167080
关键词：
AreaComputer Retrieval of Information on Scientific Projects DatabaseFundingGrantHIV-1IndividualInstitutionPhaseRandomizedRegimenResearchResearch PersonnelResourcesSourceUnited States National Institutes of Healthefficacy evaluationopen labelprospective

项目摘要

项目成果

Judith S. Currier的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 具体目标 主要目的 证明每日一次含PI和每日一次含NNRTI方案与标准每日两次ARV治疗相比在世界不同地区HIV-1感染者初始治疗中的非劣效性。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS Primary Objective To demonstrate the non-inferiority of a once-daily PI- and a once-daily NNRTI-containing regimen as compared with standard twice-daily ARV therapy for the initial treatment of individuals infected with HIV-1 from diverse areas of the world.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
CoVPN 3008 A Phase 3, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
UCLA-CDU CFAR